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Objective To assess whether the use of selective serotonin
reuptake inhibitors (SSRIs), tricyclic antidepressants, mirtazapine,
venlafaxine or other antidepressants is associated with late elective
termination of pregnancy.
Design Case–control study using data from national registers.
Setting Denmark,Finland, andNorwayduring theperiod1996–2007.
Population A total of 14 902 women were included as cases and
148 929 women were included as controls.
Methods Cases were women with elective termination of
pregnancy at 12–23 weeks of gestation. Controls continued their
pregnancy and were matched with cases on key factors.
Main outcome measures Association between antidepressant use
during pregnancy and elective termination of pregnancy at 12–
23 weeks of gestation for fetal anomalies, or for maternal ill health
or socio-economic disadvantage.
Results At least one prescription of antidepressants was filled by
3.7% of the cases and 2.2% of the controls. Use of any type of
antidepressant was associated with elective termination of
pregnancy for maternal ill health or socio-economic disadvantage
(odds ratio, OR 2.3; 95% confidence interval, 95% CI 2.0–2.5).
Elective termination of pregnancy for fetal anomalies was associated
with the use of mirtazapine (OR 2.2, 95% CI 1.1–4.5). There was no
association between the use of any of the other antidepressants and
elective termination of pregnancy for fetal anomalies.
Conclusion The use of any type of antidepressants was associated
with elective termination of pregnancy at 12–23 weeks for
maternal ill health or socio-economic disadvantage, but not with
terminations for fetal anomalies. Further studies need to confirm
the findings concerning mirtazapine and termination of pregnancy
for fetal anomalies.
Keywords Antidepressants, fetal anomaly, socio-economic
disadvantage, termination of pregnancy.
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Introduction
Around 10% of pregnant women meet the criteria for
major depression and about 20% show high depression
scale scores, indicative of depressive symptomatology.1,2
Selective serotonin-reuptake inhibitors (SSRIs) are the most
frequently used antidepressants during pregnancy, and their
use is increasing.3,4 Some studies have reported increased
risks for congenital anomalies in association with the use
of SSRIs or tricyclic antidepressants.5–14 Risks of adverse
birth outcomes in association with other antidepressants
are largely unknown.15–17 Most of the studies that reported
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associations between antidepressants and anomalies
included data on liveborn infants only, or did not explicitly
address elective termination of pregnancy (TOP). Risks of
congenital anomalies in association with drug use might be
underestimated if TOP is not taken into consideration. On
the other hand, women on antidepressants may terminate
their pregnancy because of fear concerning teratogenic
effects.18
To assess the association between the use of antidepres-
sants and TOP we conducted a multinational case–control
study including women with a TOP at 12–23 weeks of ges-
tation as cases, and women who continued their pregnan-
cies further than their matched case as controls. We
studied associations between use of any antidepressant and
TOP, and by type of antidepressant (SSRIs, tricyclic antide-
pressants, mirtazapine, venlafaxine, and other antidepres-
sants). To elucidate the reasons for TOP we performed
stratified analyses and assessed associations with TOP
because of fetal anomalies, or because of maternal ill health
or socio-economic disadvantage.
Methods
Using a case–control study design, we selected as cases
women with a TOP at 12–23 weeks of gestation. Controls
were matched with cases by country of residence, calendar
year of pregnancy end point, age, and parity. The controls
were selected among all women who had a TOP at a later
stage than their matched case or who subsequently gave
birth.
The women were residents in Denmark, Finland, and
Norway, and ended their pregnancies between 1996 and
2007. All three countries have national registers that
include prospectively collected health and social informa-
tion on all residents. The registers include the Civil
Personal Registration (CPR) numbers, a unique number
assigned to each resident at birth or immigration. Report-
ing to the registers is mandatory and regulated by national
laws. The national parliaments have, on behalf of their
populations, given informed consent to be included in the
registers.19 We obtained data from the birth and termina-
tion of pregnancy registers, the patient registers, and the
prescription registers.
The national health registers
Data on pregnancy and maternal demographics are
included in the birth and termination of pregnancy regis-
ters, and/or the patient registers in Denmark, Finland, and
Norway.20 All liveborn births and all stillbirths after
22 weeks of gestation are recorded in the registers. In
Norway, individual data are only obtained for women with
TOP for a major risk that the fetus may suffer from a
severe disorder or for risks of harmful influences to the
woman during pregnancy.21 In Denmark and Finland
information on all terminations is recorded, together with
the reasons for TOP.22 In the registers the diagnoses and
pregnancy complications are classified according to the
national version of the International Classification of Dis-
eases (ICD), and for the period of study ICD-10 was used.
Gestational age, as recorded in the registers, was primarily
based on the first day of the last menstrual period (LMP),
as estimated by prenatal ultrasound. The prescription regis-
ters include data on dispensed item, substance, brand
name, and formulation, together with date of dispensing
for over 95% of the total outpatient population. All drugs
are classified according to the World Health Organization
Anatomical Therapeutic Chemical (ATC) classification. In
general, prescriptions are filled for a maximum of
3 months.23
Case definition, control selection, and data
collection
All women who terminated their pregnancies 84–167 days
after LMP and recorded in the registers were eligible as
cases. For each case we randomly selected ten controls
using risk-set sampling. The cases had terminated their
pregnancies between 1 January 1996 and 31 December
2007, and the controls had a continuing pregnancy at the
corresponding gestational age. The controls could be
matched with more than one case. Only pregnancies from
the years in which prescription data were available, and
when the ICD-10 coding was used in the registers, were
included. Accordingly, the years included were: Denmark
1997–2007, Finland 1996–2006, and Norway 2005–2007
(Table 1). From the registers we obtained information on
age, time of the TOP or delivery, indication for TOP, par-
ity, number of previous terminations (early or late), and
filled prescriptions of antidepressants, antidiabetics, antiepi-
leptics, and other teratogenic drugs, such as agents acting
on the renin–angiotensin system and antineoplastic agents.
Information on antineoplastic agents could not be obtained
from Denmark. Among the cases, we identified those who
had filled prescriptions with any of these drugs from
90 days prior to LMP until the TOP. Analogous informa-
tion was obtained for the controls.
Exposure variables
The antidepressants used during the study period were pre-
defined and the following were included in the analyses:
SSRIs (fluoxetine, citalopram, paroxetine, sertraline,
fluvoxamine, and escitalopram), tricyclic antidepressants
(imipramine, klomipramine, trimipramine, amitriptylin,
nortriptyline, doxepine, dosulepine, amoxapine, and
maproteline), mirtazapine, venlafaxine, and ‘other’ antide-
pressants (moklobemide, mianserine, trazodone, nefazo-
done, bupropion, milnacipran, reboxetine, and duloxetine).
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Exposure was defined as one or more filled prescriptions
from 90 days before LMP until 7 days before the TOP for
the index case.
Statistical analyses
We used conditional logistic regression analysis to estimate
associations between antidepressant use during pregnancy
and TOP. For each gestational age among the cases, controls
were matched with cases by country of residence, age, and
parity. The women selected as controls could either have
had a TOP at a later gestational week than the case that they
were matched with or had given birth. Comparisons were
made between cases and controls concerning exposure to
any antidepressant and by type of antidepressant. The con-
trols followed the case strata that they were matched with,
throughout the analyses. Type of antidepressant was
grouped as: (1) SSRI; (2) tricyclic antidepressants; (3) mirt-
azapine; (4) venlafaxine; or (5) other antidepressants.
The analyses were performed using two models: one
including the matching variables (model 1) and the other
additionally adjusting for use of antidiabetics, antiepileptics,
or other teratogenic drugs (model 2). Women with missing
data were excluded from the multivariate analysis. For
women exposed to only one type of antidepressant during
the exposure period, the odds ratios (ORs) are presented
together with 95% confidence intervals (95% CIs) in Tables
2 and 3. In addition, 99% CIs were computed. We analysed
associations between use of any antidepressant and TOP by
type of antidepressant, and in stratified analyses by the rea-
son for the TOP, i.e. fetal anomalies, or maternal ill health
or socio-economic disadvantage. For exposure to any anti-
depressant we further explored whether a history of previ-
ous TOP or whether young age (i.e. below 20 years of age)
influenced the associations with TOP. Lastly, the effect of
narrowing the exposure period from 90 days before to
30 days before LMP was evaluated.
All analyses were conducted using SAS 9.3 (SAS Institute
Inc., Cary, NC, USA). The study was approved (no. 2008/
1371-31/4) by the Regional Ethical Review Board at Karo-
linska Institutet in Stockholm, Sweden, the National Board
of Health, Denmark, the Danish Data Protection Agency,
the National Institute for Health and Welfare of Finland,
Statistics Finland, and the Norwegian Data Inspectorate.
Results
A total of 14 902 women with TOP were included as cases
and 148 929 women were included as controls. Characteris-
tics of the women included are presented in Table 1. The
mean age was 28.1 years and of the 163 831 women,
30 340 (18.5%) were younger than 20 years of age. Previ-
ous TOP was more common among cases than among
controls (19.8 versus 0.2%). Among the cases, 13 231
(88.8%) had a TOP before 20 weeks of gestation. The rea-
son for TOP was recorded for 94.8%: 40% had a TOP for
fetal anomalies, and 60% had a TOP for maternal ill health
or socio-economic disadvantage. At least one prescription
of antidepressants was filled by 550 (3.7%) of the cases, as
compared with 3275 (2.2%) of the controls. SSRIs were the
most commonly used antidepressants, both among cases
(71.3%) and controls (76.8%).
Exposure to any antidepressant was associated with TOP
(OR 1.7, 95% CI 1.6–1.9; Table 2). An association was
found in all drug groups, although the associations with
tricyclic antidepressants and with other antidepressants
were imprecise. The highest OR was in association with
exposure to venlafaxine (OR 3.3, 95% CI 2.3–4.7). All risk
estimates were unchanged or slightly attenuated when
adjusting for exposure to antidiabetics, antiepileptics, or
other teratogenic drugs (model 2).
In the stratified analyses by reason for TOP we observed
no association with the use of any antidepressants or spe-
cifically with SSRIs and TOP for fetal anomalies (Table 3).
Few women had been exposed to the other antidepressant
drug groups. Women exposed to mirtazapine had a dou-
bled OR of TOP because of fetal anomaly (OR 2.2, 95% CI
1.1–4.5, 99% CI 0.9–5.7). Any antidepressant use more
than doubled the OR of TOP for maternal ill health or
socio-economic disadvantage (OR 1.8–5.1).
Stratifying for one or more previous terminations yielded
almost identical risk estimates among women with a previ-
ous TOP and among women without a previous TOP. For
women with no previous termination the OR of TOP for
fetal anomaly by antidepressant use was 1.0 (95% CI 0.9–
1.3), and for women with previous TOP the OR was 1.0
(95% CI 0.4–2.8). When considering TOP because of
maternal ill health or socio-economic disadvantage, women
with no previous TOP had an OR of 1.9 (95% CI 1.6–2.1),
by antidepressant use. The corresponding OR among
women with previous TOP was 2.0 (95% CI 1.1–3.5).
Exposure to any antidepressants below 20 years of age
yielded an OR for a TOP, irrespective of reason, of 0.7
(95% CI 0.5–1.0). The corresponding OR for women aged
20 years or older was 1.9 (95% CI 1.7–2.1). Setting the
start of the exposure period to 30 days before LMP had
only minor influence on the risk estimates (OR 1.7, 95%
CI 1.6–1.9). Excluding neoplastic agents from the definition
of other teratogenic drugs in an analysis restricted to Fin-
land and Norway, the countries where such information
could be obtained, did not influence the risk estimates.
Discussion
Main findings
In this register-based study assessing associations between
TOP at 12–23 weeks of gestation and exposure to antide-
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Table 2. Exposure to antidepressants and odds ratios for termination of pregnancy by type of drug
Type of drug No. of women exposed to
antidepressants (per 1000)
Odds ratio (95% CI)
Cases Controls Model 1* Model 2**
Any antidepressant 550 (36.9) 3275 (22.0) 1.7 (1.6–1.9) 1.7 (1.5–1.8)
SSRI*** 392 (26.3) 2515 (16.9) 1.6 (1.4–1.8) 1.6 (1.4–1.7)
Tricycllic antidepressant 23 (1.5) 174 (1.2) 1.3 (0.9–2.1) 1.3 (0.8–1.9)
Mirtazapine 34 (2.3) 130 (0.9) 2.7 (1.8–3.9) 2.6 (1.8–3.9)
Venlafaxine 38 (2.5) 119 (0.8) 3.3 (2.3–4.7) 3.0 (2.1–4.3)
Other antidepressants**** 15 (1.0) 95 (0.6) 1.6 (0.9–2.8) 1.5 (0.9–2.7)
*Adjusted by conditioning for gestational age in weeks, country of residence, year, maternal age and parity.
**Adjusted by conditioning, as in model 1, and for use of antidiabetics, antiepileptics, or other teratogenic drugs (ATC-codes C09, L01, or L04).
***Selective serotonin reuptake inhibitor.
****Moklobemide, mianserin, trazodone, nefazodone, bupropion, milnacipran, reboxetine, or duloxetine.
Table 1. Maternal characteristics
Characteristics No. (%) of cases
(n = 14 902)
No. (%) of controls
(n = 148 929)
Total no. (%)
(n = 163 831)
Country of residence (years of inclusion)
Denmark (1997–2007) 6567 (44.1) 65 588 (44.0) 72 155 (44.0)
Finland (1996–2006) 7747 (52.0) 77 461 (52.0) 85 208 (52.0)
Norway (2005–2007) 588 (3.9) 5880 (3.9) 6468 (3.9)
Maternal age (years)
≤24 5532 (37.1) 55 311 (37.1) 60 843 (37.1)
25–34 5755 (38.6) 57 547 (38.6) 63 302 (38.6)
35–44 3543 (23.8) 35 428 (23.8) 38 971 (23.8)
≥45 72 (0.5) 643 (0.4) 715 (0.4)
Parity
1 8802 (59.1) 87 940 (59.0) 96 742 (59.0)
2 or 3 4960 (33.3) 49 599 (33.3) 54 559 (33.3)
≥4 1140 (7.6) 11 390 (7.6) 12 530 (7.6)
Previous termination of pregnancy
0 11 946 (80.2) 148 633 (99.8) 160 579 (98.0)
1 2127 (14.3) 232 (0.2) 2359 (1.4)
≥2 829 (5.6) 64 (0.0) 893 (0.5)
Maternal use of antidepressants*
No 14 352 (96.3) 145 654 (97.8) 160 006 (97.7)
Yes 550 (3.7) 3275 (2.2) 3825 (2.3)
Maternal use of drugs for diabetes**
No 14 765 (99.1) 148 087 (99.4) 162 852 (99.4)
Yes 137 (0.9) 842 (0.6) 979 (0.6)
Maternal use of drugs for epilepsy***
No 14 737 (98.9) 148 091 (99.4) 162 828 (99.4)
Yes 165 (1.1) 838 (0.6) 1003 (0.6)
Maternal use of other teratogenic drugs****
No 14 855 (99.7) 148 728 (99.9) 163 583 (99.8)
Yes 47 (0.3) 201 (0.1) 248 (0.2)
*ATC-code N06A, **ATC-code A10, ***ATC-code N03A, ****agents acting on the renin-angiotensin system and antineoplastic agents (ATC-
codes C09, L01, or L04).
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pressants, we found associations with SSRIs, with mirtaza-
pine, and with venlafaxine. Most importantly the positive
associations were mainly apparent when the reason for
TOP was maternal ill health or socio-economic disadvan-
tage.
Strengths and limitations
Major strengths of the study include its multinational and
population-based design, and the assessment of covariates
such as young age and previous TOP. We used a case–con-
trol design and included as cases all women who had a TOP
after gestational week 12 in three Nordic countries during
the study period. Information on exposure to antidepres-
sants and characteristics was prospectively collected, exclud-
ing the common validity concerns related to case–control
studies because of recall bias. The design allowed us to
match for important factors such as country of residency,
year of pregnancy, age, and parity, and to take into consid-
eration gestational week when terminating the pregnancy.
The controls had either given birth to a child or terminated
their pregnancy at a later stage than the cases. Previous
studies assessing TOP have been criticised for comparisons
with women who have given birth, as the ideal comparator
should be any pregnant woman.22 It is, however, unlikely
that not including women with spontaneous abortions
should have influenced the associated risks, as late sponta-
neous abortions occur in <2% of all pregnancies.24
Ultrasound scanning has been part of the standard ante-
natal care in the Nordic countries for several decades, and
the ability to detect fetal anomalies by ultrasound has
increased over the years.25,26 In Denmark and Norway a
woman may terminate her pregnancy before 13 weeks of
gestation upon request; in Finland, a legal indication is
required for early TOP.22 In each country, later TOP is also
possible for reasons of fetal anomaly, maternal ill health,
and social or ethical circumstances, provided that permis-
sion from a national/regional decision-making committee
is granted. Despite the clear distinction between early and
late TOP in legal terms, one should acknowledge the
uncertainty of estimation of gestational age, even by ultra-
sound scanning. In a study from Finland, with overlapping
data from the present study, TOP for fetal reasons were
slightly more common among SSRI users;14 however, that
study did not assess other reasons for TOP, and included
both early and late terminations. Women on SSRIs might
terminate their pregnancies for other reasons than fetal
anomaly, such as fear of teratogenic effects of the drug,
and therefore it is important to study other reasons for
TOP as well. Also, as in this study, preferably only the later
terminated pregnancies should be evaluated, as in contrast
to early TOP they are most likely to be performed after an
ultrasound examination, thereby verifying the suspicion of
a fetal anomaly.
We did not have information on the reason for treat-
ment or details of treatment. Hence it is possible that
residual confounding by these unmeasured factors affected
our risk estimates. Although information on dispensed
drugs is not the same as intake of drugs, Nordic studies
Table 3. Exposure to antidepressants and odds ratio for termination of pregnancy by type of drug and reason for termination
Reason for termination
of pregnancy
Drug class No. of women exposed to
antidepressants (per 1000)
Odds ratio (95% CI)
Cases Controls Model 1* Model 2**
Fetal anomaly Any antidepressant 134 (23.7) 2341 (21.7) 1.1 (0.9–1.3) 1.0 (0.9–1.3)
SSRI*** 95 (16.8) 1792 (16.6) 1.0 (0.8–1.2) 1.0 (0.8–1.2)
Tricyclic antidepressant 8 (1.4) 129 (1.2) 1.0 (0.5–2.1) 1.0 (0.5–2.0)
Mirtazapine**** 9 (1.6) 83 (0.8) 2.2 (1.1–4.5) 2.2 (1.1–4.5)
Venlafaxine 6 (1.1) 92 (0.9) 1.2 (0.5–2.7) 1.2 (0.5–2.7)
Other antidepressants***** 6 (1.1) 66 (0.6) 1.6 (0.7–3.8) 1.6 (0.7–3.7)
Maternal ill health
or socio-economic
disadvantage
Any antidepressant 395 (46.6) 2674 (21.5) 2.3 (2.0–2.5) 2.2 (2.0–2.5)
SSRI*** 286 (33.8) 2078 (16.7) 2.1 (1.8–2.4) 2.0 (1.8–2.3)
Tricyclic antidepressant 13 (1.5) 131 (1.1) 1.8 (1.0–3.2) 1.7 (0.9–3.0)
Mirtazapine 25 (3.0) 111 (0.9) 3.1 (2.0–4.8) 3.1 (2.0–4.7)
Venlafaxine 29 (3.4) 96 (0.8) 5.1 (3.4–7.9) 4.6 (3.0–7.1)
Other antidepressants***** 8 (0.9) 69 (0.6) 1.9 (0.9–3.9) 1.8 (0.8–3.7)
*Adjusted by conditioning for gestational age in weeks, country of residence, year, maternal age, and parity.
**Adjusted by conditioning, as in model 1, and for use of antidiabetics, antiepileptics, or other teratogenic drugs (ATC-codes C09, L01, or L04).
***Selective serotonin reuptake inhibitor.
****99% CI included 1.0.
*****Moklobemide, mianserin, trazodone, nefazodone, bupropion, milnacipran, reboxetine, or duloxetine.
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showed good agreement of maternal antidepressant use,
when comparing information on dispensed drugs with
reported drug intake.27,28 Exposure to more than one
antidepressant was not assessed, but considering the short
periods for evaluating exposure switching of antidepres-
sants or add-on therapy should not be a major concern.
The reasons for TOP could only be assessed for residents
in Denmark and Finland, which, nonetheless, constituted
more than 96% of the study population.
Interpretation
With a few exceptions, studies on the use of SSRIs and
congenital anomalies have been based only on pregnancies
resulting in the birth of a live child.5–13 If a pregnancy is
terminated for severe anomalies caused by a drug, and
associations between the drug and the anomalies are based
on live births only, such associations would yield underesti-
mated risk estimates.
We found a doubled OR for TOP in association with
maternal use of antidepressants. The association was only
apparent in women aged 20 years or older, so pregnant
teenagers terminating their pregnancies seem to do so inde-
pendently of the use of antidepressants, which was also the
case for women with a previous TOP. The majority of
the women exposed to antidepressants had used SSRIs, and
the OR associated with the use of an SSRI was in line with
the use of any antidepressant.
In the analyses, where we stratified for reasons of TOP,
the association seemed mainly to be driven by the associa-
tion found for the use of antidepressants in women with ill
health or socio-economic disadvantage. In particular, there
was no association between TOP because of fetal anomalies
and SSRI use, whereas the OR was increased two-fold for
mirtazapine. It should be noted that for all of the drug
groups the ORs were around twice as high for TOP
because of ill health or socio-economic disadvantage than
the estimates for TOP for fetal anomalies. As the associa-
tion between TOP for fetal anomalies and use of mirtaza-
pine was not statistically significant when applying the
stricter level of significance (99% CI), this finding should
be interpreted cautiously and evaluated further.17
The SSRIs are the most commonly used antidepressants
during pregnancy, and our findings do not indicate an
association between the use of SSRIs and TOP for fetal
anomalies. Furthermore, we speculate that the mere use of
antidepressants may cause concern about an adverse preg-
nancy outcome and make the pregnant woman and her
doctor choose to terminate the pregnancy. An alternative
explanation to our findings of an association between TOP
for maternal reasons and use of antidepressants could be
related to depression or depression-related symptoms
despite medication, or other chronic diseases. Such an
explanation is less likely as difficulties in managing the dis-
ease generally should be preceded by a change in treatment,
such as a switching of antidepressant, which rarely happens
during pregnancy.4,29 Also, adjusting for the use of drugs
considered to be teratogenic and used to treat other
chronic conditions, such as diabetes, epilepsy, and other
autoimmune diseases, had only minor effects on the ORs.
Conclusion
We found associations between late TOP and the use of
antidepressants, such as SSRIs, venlafaxine, and mirtaza-
pine. In women using SSRIs, the association was only
apparent in women with a TOP for maternal ill health or
socio-economic disadvantage. Conversely, the use of mirt-
azapine may be associated with termination for fetal anom-
alies. As SSRIs were not associated with elective
termination for fetal anomalies, women treated with these
drugs and their doctors should feel less stressed out about
fetal outcomes. Further studies assessing associations
between the newer antidepressants and congenital anoma-
lies, such as mirtazapine, are warranted.
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